A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality
Authors:
- 24 January 2011
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (12) , 1545-1550
Abstract
The estimated frequency of parainfluenza virus 3 (PIV-3) infections following haematopoietic SCT (HSCT) is 2–7%, whereas reported mortality ranges from 18 to 33%. We report a retrospective outcome analysis following an outbreak of PIV-3 infection in our transplant unit. A total of 16 HSCT patients developed PIV-3 infection. All patients had upper respiratory tract infection, whereas lower respiratory tract infection occurred in 8 patients. Overall, 13 patients were treated with aerosolised Ribavirin (2 g t.d.s. for 5 days) and i.v. Ig (0.5 g/kg) as per standard protocol. One patient refused treatment, whereas two patients with full immune reconstitution were not treated. Overall mortality was 62.5%. Sepsis with multi-organ failure and the presence of pulmonary co-pathogens were both significantly associated with PIV-3-related mortality. Our series confirms that high mortality is associated with PIV-3 infection in HSCT recipients. In patients who develop PIV-3 infection, despite strict enforcement of infection control policies, the best strategy might be careful risk assessment, with effective broad-spectrum anti-microbials in those who are at risk of secondary infection.Keywords
This publication has 24 references indexed in Scilit:
- Effect of Hemagglutinin-Neuraminidase Inhibitors BCX 2798 and BCX 2855 on Growth and Pathogenicity of Sendai/Human Parainfluenza Type 3 Chimera Virus in MiceAntimicrobial Agents and Chemotherapy, 2009
- Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infectionBlood, 2007
- Long‐term therapy with aerosolized ribavirin for parainfluenza 3 virus respiratory tract infection in an infant with severe combined immunodeficiencyPediatric Transplantation, 2006
- Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmesBone Marrow Transplantation, 2004
- Mutations in Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase Causing Increased Receptor Binding Activity and Resistance to the Transition State Sialic Acid Analog 4-GU-DANA (Zanamivir)Journal of Virology, 2003
- Respiratory virus infections in transplant recipients after reduced‐intensity conditioning with Campath‐1H: high incidence but low mortalityBritish Journal of Haematology, 2002
- Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International ConsensusClinical Infectious Diseases, 2002
- Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow TransplantationBone Marrow Transplantation, 2001
- Parainfluenza Virus 3 Infection after Stem Cell Transplant: Relevance to Outcome of Rapid Diagnosis and Ribavirin TreatmentClinical Infectious Diseases, 2001
- Epidemiology and Clinical Impact of Parainfluenza Virus Infections in Otherwise Healthy Infants and Young Children < 5 Years OldThe Journal of Infectious Diseases, 1997